How should I manage a fasting diabetic patient with a blood glucose of 93 mg/dL and elevated ketones (on an SGLT2 inhibitor)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Immediate Management: Euglycemic Diabetic Ketoacidosis (DKA)

This patient with a blood glucose of 93 mg/dL, elevated ketones, and SGLT2 inhibitor use has euglycemic DKA and requires immediate hospitalization, discontinuation of the SGLT2 inhibitor, and initiation of intravenous insulin with dextrose-containing fluids to suppress ketogenesis. 1, 2, 3

Critical Recognition

This clinical scenario represents euglycemic DKA, a dangerous complication where ketoacidosis develops despite normal or near-normal glucose levels (typically <200 mg/dL). SGLT2 inhibitors promote this by:

  • Increasing urinary glucose excretion (60-100g/day)
  • Shifting metabolism toward lipolysis and ketogenesis
  • Elevating glucagon levels while lowering insulin
  • Reducing renal ketone excretion 1, 4

The "euglycemic" presentation makes this easily missed—clinicians expect DKA to present with glucose >250 mg/dL, but up to 71% of SGLT2i-associated DKA cases present with glucose ≤250 mg/dL 2.

Immediate Diagnostic Workup

Obtain immediately:

  • Blood β-hydroxybutyrate (preferred over urine ketones—nitroprusside methods miss β-OHB, the predominant ketone) 5, 6, 3
  • Venous blood gas (arterial unnecessary; venous pH typically 0.03 units lower)
  • Complete metabolic panel with anion gap calculation
  • Blood glucose, electrolytes (especially potassium)
  • Serum osmolality 5, 6

DKA diagnostic criteria: pH <7.3, bicarbonate <15-18 mEq/L, elevated ketones, with anion gap metabolic acidosis 5, 6

Treatment Protocol

1. Stop the SGLT2 Inhibitor Immediately

Permanently discontinue—patients who develop DKA should not be re-challenged 2, 4

2. Fluid Resuscitation

  • Initiate isotonic saline (0.9% NaCl) for volume repletion
  • Assess hydration status and hemodynamics
  • Replace sodium-containing fluids to prevent intravascular volume depletion 7, 3

3. Insulin Therapy with Dextrose

This is the critical difference from hyperglycemic DKA:

  • Start continuous IV insulin infusion (regular insulin 0.1 units/kg/hour) 5, 6
  • Simultaneously start 5% dextrose in 0.45% saline to prevent hypoglycemia while suppressing ketogenesis 3, 8
  • The dextrose is essential—insulin suppresses ketone production, but without glucose supplementation at this blood sugar level, severe hypoglycemia will occur
  • Monitor glucose hourly; adjust dextrose concentration (5-10%) to maintain glucose 150-200 mg/dL 5, 6

4. Potassium Replacement

  • Do not start insulin if K+ <3.3 mEq/L—correct first
  • If K+ 3.3-5.3 mEq/L: add 20-30 mEq/L to IV fluids (use 1/3 KPO4, 2/3 KCl)
  • Monitor K+ every 2-4 hours 5, 6

5. Monitor Resolution

Check every 2-4 hours:

  • Blood glucose
  • Electrolytes and anion gap
  • Venous pH
  • β-hydroxybutyrate (if available) 5, 6

Resolution criteria: glucose <200 mg/dL, bicarbonate ≥18 mEq/L, venous pH >7.3, closed anion gap 5, 6

Common Pitfalls

  1. Missing the diagnosis because glucose is "normal"—always check ketones in SGLT2i patients with unexplained acidosis, nausea, vomiting, or abdominal pain 3, 9

  2. Delaying insulin because glucose is low—insulin is needed to suppress ketogenesis, not just lower glucose 3, 8

  3. Forgetting dextrose—without it, hypoglycemia will occur before ketosis resolves 8

  4. Using urine ketones alone—they miss β-OHB and can falsely suggest worsening during treatment as β-OHB converts to acetoacetate 5, 6

  5. Stopping insulin too early—ketone clearance takes longer than glucose normalization. Continue IV insulin 1-2 hours after starting subcutaneous insulin to ensure adequate overlap 5, 6

Prevention for Future Patients

SGLT2 inhibitors should be held during:

  • Fasting states (including perioperative—stop 3-4 days before elective surgery) 10, 11, 12
  • Acute illness, infection, dehydration 1, 2, 4
  • Very low-carbohydrate/ketogenic diets 2, 4
  • Excessive alcohol intake 2, 4

Educate patients on "sick day rules": stop SGLT2i, maintain hydration and carbohydrate intake (150-200g/day), continue insulin, test ketones if glucose >300 mg/dL or feeling unwell 7, 13, 4

Risk Context

While euglycemic DKA is rare in type 2 diabetes (0.6-4.9 per 1,000 person-years), it carries significant morbidity when missed 2, 4. The risk is substantially higher in insulin-deficient states, during physiologic stress, and with fasting 2, 4, 12.

References

6
Guideline

hyperglycemic crises in diabetes.

Diabetes Care, 2004

Related Questions

In a dehydrated patient, should the SGLT2 inhibitor be discontinued?
Explain euglycemic ketoacidosis caused by SGLT‑2 inhibitors.
Is it appropriate to give the patient oral intake while she remains on an insulin infusion, given that her anion gap is now 14 (within normal range)?
Can Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors be given to patients with type 2 diabetes mellitus during an acute infection?
Can a patient with pyuria who is afebrile and asymptomatic and has an HbA1c of 14.2% be started on a sodium‑glucose co‑transporter‑2 (SGLT‑2) inhibitor?
In a patient with diabetes mellitus and hypertension who develops elevated ketones while fasting, how should the fasting be managed and what treatment steps are recommended?
What is the recommended dosing regimen of Polytrim (polymyxin B 0.1 %/trimethoprim 0.025 %) for a corneal abrasion in adults, children older than six months, and infants younger than six months, and what alternative topical antibiotic should be used in patients with a sulfonamide allergy?
What is the cause of recurrent kidney stones in a patient on long‑term hydrochlorothiazide therapy?
How should a female patient with autoimmune hypothyroidism and hyperinsulinemia be evaluated and managed for recurrent hypoglycemia?
How should recurrent hypoglycemia be evaluated and treated in a patient with metastatic breast cancer to bone and autoimmune thyroid disease?
What are the recommended dosages of fish‑oil (EPA/DHA) and curcumin (with piperine) for treating scalp psoriasis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.